Fairvoy Private Wealth LLC Increases Position in Abbott Laboratories $ABT

Fairvoy Private Wealth LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 1.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 28,834 shares of the healthcare product maker’s stock after buying an additional 359 shares during the period. Fairvoy Private Wealth LLC’s holdings in Abbott Laboratories were worth $3,922,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ABT. Brighton Jones LLC lifted its stake in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the period. Cypress Wealth Services LLC increased its position in Abbott Laboratories by 3.3% during the first quarter. Cypress Wealth Services LLC now owns 3,021 shares of the healthcare product maker’s stock worth $401,000 after purchasing an additional 97 shares during the last quarter. Retirement Planning Group LLC increased its position in Abbott Laboratories by 6.7% during the first quarter. Retirement Planning Group LLC now owns 3,332 shares of the healthcare product maker’s stock worth $442,000 after purchasing an additional 209 shares during the last quarter. Breakwater Capital Group acquired a new position in Abbott Laboratories during the first quarter worth approximately $592,000. Finally, Vest Financial LLC increased its position in Abbott Laboratories by 5.6% during the first quarter. Vest Financial LLC now owns 528,489 shares of the healthcare product maker’s stock worth $70,104,000 after purchasing an additional 28,176 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $134.49 on Friday. The company has a market capitalization of $234.07 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. The firm has a fifty day simple moving average of $131.94 and a 200-day simple moving average of $131.33. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio is 29.57%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Leerink Partners assumed coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They set a “market perform” rating and a $143.00 price target for the company. BTIG Research dropped their price target on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, July 18th. Mizuho increased their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 16th. Wells Fargo & Company dropped their price objective on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research report on Friday, July 18th. Finally, Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $145.39.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.